Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CLPP | Q16740 | 5/20 | 0.50 |
| ▸ | MMP13 | P45452 | 4/20 | 0.43 |
| ▸ | DRD2 | P14416 | 1/20 | 0.40 |
| ▸ | DRD4 | P21917 | 1/20 | 0.40 |
| ▸ | DRD3 | P35462 | 1/20 | 0.40 |
| ▸ | C5AR1 | P21730 | 1/20 | 0.40 |
| ▸ | ACHE | P22303 | 1/20 | 0.39 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.39 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.39 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.39 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6497781 | 0.96 | CLPP (0.52) | CLPPMMP13DRD2DRD4DRD3 | |
| SCHEMBL6493997 | 0.95 | CLPP (0.50) | CLPPMMP13DRD2DRD4CYP11B2 | |
| SCHEMBL6484792 | 0.95 | CLPP (0.47) | CLPPMMP13GABRA1GABRA2CYP11B2 | |
| SCHEMBL6490318 | 0.92 | CLPP (0.47) | CLPPMMP13DRD2DRD4DRD3 | |
| SCHEMBL6497860 | 0.92 | CLPP (0.45) | CLPPMMP13DRD2DRD4CYP11B2 | |
| SCHEMBL6487309 | 0.91 | CLPP (0.55) | CLPPMMP13DRD2DRD4CYP11B2 | |
| SCHEMBL6490608 | 0.91 | CLPP (0.47) | CLPPMMP13DRD2DRD4DRD3 | |
| SCHEMBL6500861 | 0.91 | MMP13 (0.56) | CLPPMMP13CYP11B2 | |
| SCHEMBL6494214 | 0.91 | CLPP (0.59) | CLPPMMP13CYP11B2 | |
| SCHEMBL6502771 | 0.90 | CLPP (0.54) | CLPPMMP13DRD2DRD4DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6869958-B2 | Fused tetrahydropyridine derivatives as matrix metalloproteinase inhibitors | WARNER-LAMBERT COMPANY (US) | 2005-03-22 | — | — | US | disclosed |
| US-20040038960-A1 | Fused tetrahydropyridine derivatives as matrix metalloproteinase inhibitors | LI JIE JACK (US) | 2004-02-26 | — | — | US | disclosed |
| WO-2004014909-A1 | FUSED TETRAHYDROPYRIDINE DERIVATIVES AS MATRIX METALLOPROTEINASE INHIBITORS | WARNER-LAMBERT COMPANY LLC (US) | 2004-02-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040038960-A1 | Fused tetrahydropyridine derivatives as matrix metalloproteinase inhibitors | MMP9, MMP3, MMP13 | CLPP 3602/4885MMP13 3/4885DRD2 963/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.